A(tri)-sp | 141468-21-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: A(tri)-sp
• 英文别名: 3-aminopropyl O-(2-acetamido-2-deoxy-α-D-galactopyranosyl)-(1→3)-[O-(α-L-fucopyranosyl)-(1→2)]-β-D-galactopyranoside
• CAS: 141468-21-5
• 化学式: C₂₃H₄₂N₂O₁₅
• 分子量: 586.591
• InChiKey: YDBNUXCDKXGSRB-OVEUNJANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.03
• 重原子数：
  40.0
• 可旋转键数：
  11.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  272.34
• 氢给体数：
  10.0
• 氢受体数：
  16.0

反应信息

• 作为反应物：
  描述：

  A(tri)-sp 在 吡啶 、 sodium acetate 、 乙酸肼 、 溶剂黄146 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 294.83h， 生成 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl-(1->3)-[2,3,4-tri-O-acetyl-α-L-fucopyranosyl-(1->2)]-4,6-di-O-acetyl-β-D-galactopyranoside trichloroacetimidate
  参考文献：
  名称：

  Block synthesis of A tetrasaccharides (types 1, 3, and 4) related to the human ABO blood group system

  摘要：

  Blood group A tetrasaccharides of different types have the same terminal trisaccharide fragment that allows using a block scheme in their synthesis. 3-Aminopropyl glycosides of tetrasaccharides GalNAc alpha 1-3(Fuc alpha 1-2)Gal beta 1-3GlcNAc beta (A type 1), GalNAc alpha 1-3(Fuc alpha 1-2)Gal beta 1-3GalNAc alpha (A type 3), and GalNAc alpha 1-3(Fuc alpha 1-2)Gal beta 1-3GalNAc beta (A type 4) were synthesised using acetylated Gal alpha 1-3(Fuc alpha 1-2)Gal trichloroacetimidate as a glycosyl donor at the key stage. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2011.12.013
• 作为产物：
  描述：

  在 20% palladium hydroxide-activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以155 mg的产率得到A(tri)-sp
  参考文献：
  名称：

  带有氨基间隔臂的血型抗原，ABO组织血型II型抗原和异种抗原寡糖的快速合成

  摘要：

  血型寡糖是临床上最重要的抗原家族之一，它们还可作为大肠杆菌和霍乱弧菌细菌毒素的二级配体。在此，我们报告了A抗原{α-D-GalNAc-（1→3）-[α-L-Fuc-（1→2）]-的间隔（sp = CH 2 CH 2 CH 2 NH 2）糖苷的合成β-D-Gal-}，B抗原{α-D-Gal-（1→3）-[α-L-Fuc-（1→2）]-β-D-Gal-}，LewisX {α-D -Gal-（1→4）-[α-L-Fuc-（1→3）]-β-D-GlcNAc-}，II型{α-D-GalNAc-（1→3）-[α -L-Fuc-（1→2）]-β-D-Gal-（1→4）-β-D-GlcNAc-}，B型{α-D-Gal-（1→3）-[α-L-Fuc-（1→2）]-β-D-Gal-（1→4）-β-D-GlcNAc-}，H型II {α-L-Fuc-（1→2）-β-d-GAL-（1→4）-β-d-GlcNAc-}

  DOI：

  10.1007/s10719-015-9635-1

文献信息

• [EN] GLYCOPOLYMERS SEQUESTERING CARBOHYDRATE-BINDING PROTEINS<br/>[FR] GLYCOPOLYMÈRES SÉQUESTRANT DES PROTÉINES DE LIAISON AUX GLUCIDES
  申请人：POLYNEURON PHARMACEUTICALS AG

  公开号：WO2018167230A1

  公开（公告）日：2018-09-20

  The invention relates to polymers comprising carbohydrate ligands and moieties, respectively, that bind to carbohydrate-binding proteins (CBPs), as well as to these carbohydrate ligands, and to their use in diagnosis and therapy of diseases that are associated with CBP-mediated cytotoxicity, agglutinatination, or immune complex deposit formation. In particular, the invention relates to polymers comprising a multitude of said carbohydrate ligands and moieties, respectively, mimicking carbohydrates that are bound by CBPs which belong to the group of (i) bacterial exotoxins, (ii) agglutinins, and (iii) immune complex deposit-forming immunoglobulins. Furthermore, the invention relates to the use of these polymers and carbohydrate ligands and moieties respectively, in diagnosis as well as for the treatment of diseases that are associated with CBP-mediated cytotoxicity, agglutinatination, or immune complex deposit formation. In one embodiment, the polymer is polylysine.

  该发明涉及包含与结合碳水化合物结合蛋白（CBP）的碳水化合物配体和基团的聚合物，以及这些碳水化合物配体的使用，以及它们在与CBP介导的细胞毒性、凝集素作用或免疫复合物沉积形成相关的疾病的诊断和治疗中的应用。具体而言，该发明涉及包含大量所述碳水化合物配体和基团的聚合物，分别模拟被属于（i）细菌外毒素、（ii）凝集素和（iii）免疫复合物沉积形成免疫球蛋白所结合的碳水化合物。此外，该发明涉及在诊断以及治疗与CBP介导的细胞毒性、凝集素作用或免疫复合物沉积形成相关的疾病中使用这些聚合物和碳水化合物配体和基团。在一种实施方式中，聚合物是聚赖氨酸。
• [EN] SYNTHETIC MEMBRANE ANCHORS<br/>[FR] ELEMENTS D'ANCRAGE DE MEMBRANES SYNTHETIQUES
  申请人：KIWI INGENUITY LTD

  公开号：WO2005090368A1

  公开（公告）日：2005-09-29

  The invention relates to synthetic molecules that spontaneously and stably incorporate into lipid by-layers, including cell membranes. Particularly, although not exclusively, the invention relates to the use of these molecules as synthetic membrane anchors or synthetic molecule constructs to effect qualitative and quantitative changes in the expression of cell surface antigens.

  该发明涉及合成分子，这些分子自发且稳定地嵌入到脂质双层中，包括细胞膜。特别地，虽然不限于此，该发明涉及使用这些分子作为合成膜锚或合成分子构建物，以影响细胞表面抗原的表达的定性和定量变化。
• [EN] BIOSURFACE ENGINEERING<br/>[FR] INGÉNIÉRIE DE BIOSURFACE
  申请人：BOVIN NICOLAI VLADIMIROVICH

  公开号：WO2012099477A1

  公开（公告）日：2012-07-26

  The invention relates to methods of localising biofunctional moieties (F) to surfaces and synthetic constructs of the general structure F-S-S' for use in such methods. F is the biofunctional moiety, S is a spacer covalently linking F to S', and S' is sterol. In particular, the invention relates to the preparation of biofunctional surfaces and surface modified biological structures including cells (kodecytes), enveloped viruses (kodevirions) and liposomes or virosomes (kodesomes).

  本发明涉及用于将生物功能基团（F）定位于表面和具有F-S-S'一般结构的合成构造物的方法，其中F是生物功能基团，S是将F与S'共价连接的间隔物，而S'是甾醇。特别是，本发明涉及制备生物功能表面和表面修饰的生物结构，包括细胞（kodecytes）、包膜病毒（kodevirions）和脂质体或病毒样颗粒（kodesomes）的方法。
• Toward creating cell membrane glyco-landscapes with glycan lipid constructs
  作者：Elena Korchagina、Alexander Tuzikov、Andrey Formanovsky、Inna Popova、Stephen Henry、Nicolai Bovin

  DOI：10.1016/j.carres.2012.03.044

  日期：2012.7

  Synthetic glycolipid-like constructs dispersible in biological media and capable of incorporating into cell membranes have the ability to create novel artificial glyco-landscapes on living cells. Using a variety of different glycans ranging from disaccharides to polysaccharides, together with different lengths and high hydrophilicity spacers, we created a series of synthetic glycolipid-like constructs. Contacting these constructs with live cells gave modified cells with controlled glycan density and/or altered biological function. The ability to also use these constructs as solutions to inhibit antibodies, toxins, and virions extends the potential diagnostic and therapeutic uses for these synthetic glycolipid-like constructs. (C) 2012 Elsevier Ltd. All rights reserved.